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miR-126, miR-25, miR-205, miR-183, miR-125b) were measured by
qRT-PCR and normalized to miR-16.
Concentrations of four miRNAs (miR-19b, miR-21, miR-25,
miR-183) were significantly different in lung cancer versus
healthy individuals (p<0.05, T-test, two-sided). Two miRNAs were
upregulated (miR-19b, miR-21), two were downregulated (miR-25,
miR-183) in cancer patients. Four miRNAs (miR-19b, miR-126,
miR-25, miR-205) were found to be differentially regulated in
SCC patients when compared to healthy controls. In AC patients
only two miRNAs (miR-19b, miR-183) were differently expressed.
Thus, cancer subtypes have different input into overall picture.
Receiver Operating Characteristic (ROC) curve analysis of dif-
ferentially expressed miRNAs in total study population and
subtype-based groups showed that miR-19b has highest predic-
tive value for total population and SCC patients, while miR-183
was more effective in discriminating patients with AC. All miR-
NAs except miR-21 showed strong bias towards one of the
subtypes. Presumably a combination of miRNAs with opposite
bias should provide a more potent diagnostic tool for cancer
detection in total population than individual miRNAs or panels
of miRNAs that are specific to one cancer subtype. Indeed,
stepwise binary logistic regression has identified the combination
of miR-19b and miR-183 to be a strong prediction of disease in
total population and yielded a solid increase in AUC: 0,990
(miR-19b+miR-183) versus 0,806 (miR-19b) or 0,924 (miR-183). This
combination can be used to identify lung cancer with 94.7%
sensitivity and 95.2% specificity.
Thus, biological aspects such as tumor genetics and pheno-
type, stage of disease, response to therapy, and other meaningful
tumor properties of such heterogeneous malignancies as LC can
interfere with contents and composition of cell-free miRNA pool.
Wide profiling of circulating miRNAswill specify biomarkers of LC
phenotypes and improve non/less-invasive LC diagnostics.
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The development of individual medicine is a very important
part of the whole health care system and especially of the oncol-
ogy patients’ treatment. The predictive markers could help to
prevent the development of the different diseases. Individual risk
assessment is based on the study of polymorphisms in genes
specific to different pathologies, especially those with a signifi-
cant social impact, such as lung cancer.
Like many other cancers, lung cancer is a multi-factorial
disease. The tumor suppressor genes are important in its patho-
genesis. One such very important gene is TP53, which encodes
the p53 tumor suppressor protein. It regulates the activation of
specific cellular processes and signaling pathways involved in
regulation, recognition of signals inside the cell, coordination of
metabolic processes, genome repair, cell division and death
(apoptosis), and interactions between cells. Insufficient produc-
tion or property modification of this protein leads to the develop-
ment of serious diseases, including lung cancer.
The TP53 gene has a number of polymorphic markers; the
Arg72Pro and the Gln157Lys markers are very important in case
of lung cancer. They are located in the DNA-binding domain of
TP53 at exons that play essential structural and chemical roles
in the contact between the p53 protein and specific DNA
sequences that constitute the p53 response elements. These
mutations result in a significant loss of DNA-binding activity
and transactivation capacity (P. Hainaut and M. Hollstein, 2000).
We studied the association of polymorphic markers Arg72Pro
and Gln157Lys of TP53 gene with the risk of nonsmall cell lung
cancer (NSCLC) in patients from the Moscow region. Our study
included 88 patients with NSCLC, 160 healthy persons as a control
for Arg72Pro and 60 healthy persons as a control for Gln157Lys.
We used PCR-RLFP analysis to identify the alleles of the polymor-
phic markers.
We observed higher frequencies of the markers predisposition
genotypes in group of patients then in control group. The distri-
bution frequency of Pro/Pro genotype Arg72Pro marker was
0.307 in the group of patients and 0.075 in the control. For the
Gln157Lys marker the Lys/Lys genotype was not observed. The
frequency of Gln/Lys genotype Gln157Lys marker was 0.377 in
patients and 0.106 in the control. We found the association of
both markers with the risk of NSCLC development. The genotype
Pro/Pro of Arg72Pro marker showed the increasing of NSCLC risk:
OR = 5.46, p = 8  106. The presence of Gln/Lys genotype of
Gln157Lys marker also led to increased risk of cancer develop-
ment: OR = 5.10, p = 0.002.
Our results suggest the importance of studied polymorphic
markers for risk of NSCLC assessment. The status of the Arg72Pro
and the Gln157Lys markers of TP53 gene can serve as an indepen-
dent prognostic indicator in this type of cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.122
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Background: There is increasing evidence that BRCA1-related
DNA-repair defects determine sensitivity to certain agents, such
as platinum-based chemotherapy. There is a lot of evidence about
a link between TNBC and BRCA1 deficiency. Many clinical
characteristics and molecular features are shared by sporadic
triple-negative breast cancer and BRCA1-associated breast
cancer. The majority of BRCA1-related breast cancers are of
basal-like/triple-negative phenotype. Identification of specific
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markers of BRCA1-dysfunction will be essential to translate an
understanding of defective DNA repair into targeted treatments
for this poor prognosis subtype.
Materials and methods: Twenty-two patients with triple-
negative breast cancer (TNBC) were treated with neoadjuvant
platinum-based chemotherapy followed by surgery. Pathologic
treatment response was assessed in correlation with biomarkers
of BRCA1-dysfunction. Pathological response was evaluated
according to the Chevallier classification (Ch). All patients were
screened for germ-line mutations in BRCA1 (185delAG, 5382insC,
4153delA, 4158A/G, C61G) and BRCA2 (6174delT). All samples
negative for germ-line mutations in BRCA1 and BRCA2 then
submitted to BRCA1-dysfunction screening. Biomarkers of
BRCA1-dysfunction included: BRCA1 somatic mutations (C61G,
185delAG, 5382insC), promoter methylation of BRCA1, low BRCA1
mRNA expression, high ID4 mRNA expression, low RAD51 mRNA
expression, PTEN (T4721C) mutation, p53 (Arg72Pro, Pro72Pro)
mutations. Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR), polymerase chain reaction-single-strand
conformation polymorphism (PCR-SSCP), methylation-specific
PCR were used for BRCA1-dysfunction analysis.
Results: Twelve patients (54.5%) achieved a pathological com-
plete response (pCR) (Ch1+ Ch2). Ten patients (45.5%) had a resid-
ual disease (Ch3+ Ch4). BRCA1 mRNA expression was absent in
16/22 (72.7%) patients, low in 5/22 (22.7%). 11/21 (52.4%) patients
with other than normal BRCA1 mRNA expression achieved a
pCR. BRCA1 promoter methylation was detected in 9/22 (40.9%).
6/9 patients with BRCA1 promoter methylation achieved a pCR.
RAD51 mRNA levels were low in 14/22 (63.6%), high in 1/22
(4.5%). 8/14 (57.1%) patients with other than normal RAD51 mRNA
expression achieved a pCR.
High ID4mRNA levelswere determined in 5/22 (22.7%). 3/5 (60%)
patients with high ID4 mRNA expression achieved a pCR. p53
(Arg72Pro, Pro72Pro) mutations were identified in 12/22 (54.5%).
Nopatient had PTEN (T4721C)mutation. No statistically significant
correlation was found between the BRCA1 mRNA expression,
BRCA1 promoter methylation, RAD51 mRNA expression, high ID4
mRNA levels, p53 (Arg72Pro, Pro72Pro) mutations and pCR to
neoadjuvant platinum-based chemotherapy (p > 0.05). Eleven
patients had BRCA1 somatic mutations: 6/22 (27.3%) – BRCA1
5382insC, 4/22 (18.2%) – BRCA1 185delAG, 3/22 (13.6%) – BRCA1
C61G. 3/4 patients with BRCA1 185delAG mutation had BRCA1
C61G mutation. BRCA1 LOH was detected in 1/22 (4.5%) patient.
All patients with BRCA1 5382insC mutation achieved a pCR
(p = 0.01). All patients with BRCA1 185delAG mutation and BRCA1
C61G mutation had residual disease (0.04 and 0.1, accordingly).
Conclusion: BRCA1 5382insC somatic mutation is associated
with good response to neoadjuvant platinum based chemother-
apy (p = 0.01). BRCA1 185delAG and BRCA1 C61G mutations in
the BRCA1 RING domain may predict resistance to neoadjuvant
platinum-based chemotherapy (0.04 and 0.1, accordingly).
http://dx.doi.org/10.1016/j.ejcsup.2015.08.123
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Background: Tumor-associated macrophages play a main role
in tumor progression and dissemination. Taking into account
the high heterogeneicity of tumor the different clinical impact
of macrophages, infiltrating different sites of tumor, could be
expected. The aim was to detect the level of CD68+ cells (macro-
phages) in the different site of stroma in breast tumor in compar-
ison to clinical course.
Materials and methods: One thirty-six women with nonspeci-
fic invasive breast cancer T1-4N0-3M0, who were treated in Gen-
eral Oncology Department of Tomsk Cancer Research Institute
(Tomsk, Russia), were included in the present study. Patients did
not receive preoperative treatment. The material was fixed in
10–12% neutral formalin. Preparation of the histological material
was carried out according to standard procedures. Morphological
examination of the surgical specimens was performed by the
standard method using a light microscope ‘‘Carl Zeiss Axio Lab.
A1” (Germany) and slidescanner ‘‘MiraxMidiZeiss” (Germany).
Metastatic lesion was detected in regional lymph nodes.
Immunohistochemical study was performed according to stan-
dard procedures. Cytoplasmic expression of these markers was
determined in the inflammatory cell infiltrate of different tumor
segments: (1) in areas with soft fibrous stroma; (2) in areas with
coarse fibrous stroma; (3) in the areas of the so-called ‘‘maximum
stromal-and-parenchymal relationship” where the individual
tumor cells, short strands and groups of tumor cells arranged in
soft fibrous stroma; (4) among parenchymal elements; (5) in gaps
of ductal tumor structures. Double-stained immunofluorescence
was performed according to standard procedures using Leica
TCS SP2 laser-scanning spectral confocal microscope (Germany).
The following primary antibodies were used: mouse monoclonal
anti-human CD68 (BD Biosciences) and rabbit polyclonal anti-
stabilin-1 or RS1 (marker of M2 macrophages).
Results: The highest expression of CD68 in the inflammatory
cell infiltrate was detected more frequently in areas with soft
fibrous stroma (54%) or the so-called ‘‘maximum stromal-and-
parenchymal relationship” (79%) in patients with breast cancer.
The lowest expression of CD68 was observed in areas with coarse
fiber stroma (23%). The CD68-positive cells of the inflammatory
infiltrate were located between parenchymal elements of tumor
(88%). Inverse correlation (R = 0.67; p = 0.02) observed between
tumor size and the expression of CD68 in the cells of the inflam-
matory infiltrate in gaps of tubular tumor structures. The CD68
expression in cells of the inflammatory tumor infiltrate was cor-
related with the presence of metastatic regional lymph nodes. It
was found that in the case of the lymph node metastases the
average score of CD68 expression in cells of ductal gaps tumor
structures was lower (1.4 ± 0.5) in comparison with the negative
lymph nodes case (3.1 ± 1.0; F = 10.9; p = 0.007). Same time no cor-
relation between the CD68 expression in the inflammatory cell
tumor infiltrate and the rate of tumor malignancy was found.
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